Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835013 | 0.93 | HDAC8 (0.50) | HPGDMEN1KMT2AL3MBTL1CYP1A2 | |
| SCHEMBL2835595 | 0.92 | HDAC8 (0.52) | HPGDMEN1KMT2AL3MBTL1CYP1A2 | |
| SCHEMBL2833329 | 0.83 | GAA (0.64) | HPGDMEN1KMT2AL3MBTL1CYP1A2 | |
| SCHEMBL17202869 | 0.83 | NAMPT (0.53) | MEN1KMT2AGAAALDH1A1MAPT | |
| SCHEMBL2834391 | 0.79 | NPC1 (0.58) | HPGDMEN1KMT2AL3MBTL1ATM | |
| SCHEMBL31415849 | 0.78 | L3MBTL1 (0.55) | HPGDMEN1KMT2AL3MBTL1GAA | |
| SCHEMBL2659302 | 0.77 | CD274 (0.56) | ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL15684322 | 0.76 | APLNR (0.51) | HPGDMEN1KMT2AL3MBTL1CYP1A2 | |
| SCHEMBL13167729 | 0.76 | MAPT (0.42) | HPGDMEN1KMT2AGAAHTT | |
| SCHEMBL2836609 | 0.75 | TDP1 (0.56) | HPGDMEN1KMT2AL3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168101-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2010-07-01 | — | — | US | disclosed |
| US-7696231-B2 | Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20050043388-A1 | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. | 2005-02-24 | — | — | US | disclosed |
| EP-1439834-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037328-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043388-A1 | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) | PTPRO, PTPRE, PTPRZ1 | HPGD 1951/4885MEN1 4402/4885KMT2A 3816/4885 |
| US-20100168101-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | PTPRO, PTPRE, PTPRZ1 | HPGD 1990/4885MEN1 4405/4885KMT2A 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.